Time between non-oncology orphan drugs approval and patient access in Europe 2023
This statistic displays the average time between an non-oncology orphan medicine gaining marketing authorization and patient access in European countries as of January 5, 2023. According to the data, Germany had an average time of 78 days between authorization and access for non-oncology orphan medicines (for drugs launchend from 2018 to 2021), compared to 870 days in Estonia.